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Abstract
Mutations in POLG disrupt mtDNA replication and cause devas-
tating diseases often with neurological phenotypes. Defining
disease mechanisms has been hampered by limited access to
human tissues, particularly neurons. Using patient cells carrying
POLG mutations, we generated iPSCs and then neural stem cells.
These neural precursors manifested a phenotype that faithfully
replicated the molecular and biochemical changes found in
patient post-mortem brain tissue. We confirmed the same loss
of mtDNA and complex I in dopaminergic neurons generated
from the same stem cells. POLG-driven mitochondrial dysfunc-
tion led to neuronal ROS overproduction and increased cellular
senescence. Loss of complex I was associated with disturbed
NAD+ metabolism with increased UCP2 expression and reduced
phosphorylated SirT1. In cells with compound heterozygous POLG
mutations, we also found activated mitophagy via the BNIP3
pathway. Our studies are the first that show it is possible to
recapitulate the neuronal molecular and biochemical defects
associated with POLG mutation in a human stem cell model.
Further, our data provide insight into how mitochondrial
dysfunction and mtDNA alterations influence cellular fate deter-
mining processes.
Keywords mitochondria; mitophagy; neural stem cells; POLG; reactive oxygen
species
Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuro-
science; Stem Cells & Regenerative Medicine
DOI 10.15252/emmm.202012146 | Received 12 February 2020 | Revised 30 July
2020 | Accepted 31 July 2020
EMBO Mol Med (2020) e12146
Introduction
Mitochondria are membrane enclosed, intracellular organelles
involved in multiple cellular functions, but best known for generat-
ing adenosine triphosphate (ATP). Mitochondria are the only
organelles besides the nucleus that possess their own DNA (mito-
chondrial DNA; mtDNA) and their own machinery for synthesizing
RNA and proteins. DNA polymerase gamma, Polc, is a heterotri-
meric protein that catalyzes the replication and repair of the mito-
chondrial genome. The holoenzyme is a heterotrimer composed of
one catalytic subunit (POLG) with the size of 122 kDa, encoded by
the POLG gene, and a dimer of two accessory subunits (POLG2) of
55 kDa encoded by POLG2.
Mutations in POLG cause a wide variety of diseases that vary in
age of onset and severity. More than 200 disease-causing mutations
are known, and these cause diverse phenotypes including devastat-
ing early onset encephalopathy syndromes such as Alpers’
syndrome (Naviaux & Nguyen, 2004; Ferrari et al, 2005) or severe
adult onset disorders with progressive spinocerebellar ataxia and
epilepsy (Van Goethem et al, 2004; Hakonen et al, 2005;
Winterthun et al, 2005). Other phenotypes include progressive
external ophthalmoplegia (PEO) (Lamantea et al, 2002) and parkin-
sonism (Luoma et al, 2004). Mitochondrial dysfunction is also
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implicated in the pathophysiology of common forms of neurodegen-
eration, such as Parkinson’s disease. Studying the effect of POLG
mutation on mitochondrial function and cellular homeostasis is,
therefore, relevant to a wide spectrum of diseases.
Our previous studies using post-mortem human brain revealed
that while POLG-related disease caused widespread damage in the
brain, dopaminergic neurons of the substantia nigra were particu-
larly affected (Tzoulis et al, 2014). In addition to progressive loss,
nigral neurons also showed an age-related progressive accumula-
tion of mtDNA deletions and point mutations (Tzoulis et al,
2014). While informative, post-mortem studies often represent the
end stage of disease and are not tractable. The need for models to
study disease mechanisms is, therefore, clear, and since mouse
models often fail to recapitulate the human neural phenotype, we
chose to examine the potential of induced pluripotent stem cells
(iPSCs). IPSCs retain the potential to differentiate into any cell
type and, while still at an early developmental stage, carry the
disease mutation and the patients’ own genetic background, giving
us the possibility to study disease during tissue development
(Marchetto et al, 2011).
Primary neural stem cells (NSCs) provide a continued source of
neurons and glial cells in the brain that further serve as a founda-
tion for development, repair, and functional modulations of
human adult neurogenesis. It is not surprising, therefore, that
dysfunction of neural precursor cells contributes to an assortment
of neurological disorders (Li et al, 2018). While primary NSCs
derived from patients have the ability to circumvent immune rejec-
tion, they are hard to acquire and display a limited expansion and
engraftment capacity. A solution to this problem is the neural
induction of iPSCs to NSCs, either through an intermediate rosette-
like stage or directly by application of a cocktail of small mole-
cules (Lorenz et al, 2017). Since iPSC-derived NSCs are relatively
straightforward to generate, they provide an alternative to primary
NSCs for disease-relevant phenotype studies and drug develop-
ment (Griffin et al, 2015; Lorenz et al, 2017; Li et al, 2018). Others
have also suggested that NSC models might provide new insights
into mtDNA disorders (Kim et al, 2013).
Mitochondria conserve the energy generated by substrate oxida-
tion and use this to generate a membrane potential. The proton elec-
trochemical gradient, termed the mitochondrial membrane potential
(MMP), provides the energy that drives ATP synthesis. The MMP
also regulates mitochondrial calcium sequestration, import of
proteins into the mitochondrion and mitochondrial membrane
dynamics. Mitochondria are the major producer of superoxide and
other downstream reactive oxygen species (ROS) in the cell (Bae
et al, 2011), with the main sites of mitochondrially derived superox-
ide being complexes I and III (Brand, 2016). Mitochondrially gener-
ated ROS can mediate redox signaling or, in excess, affect
replication and transcription of mtDNA and result in a decline in
mitochondrial function, which in turn, can further enhance ROS
production (Cui et al, 2012).
Accumulating evidence demonstrates that ROS plays a critical
role in induction and maintenance of cellular senescence (Davalli
et al, 2016; Zheng et al, 2018). This state of stable cell cycle arrest,
in which proliferating cells become resistant to growth-promoting
stimuli, typically occurs in response to DNA damage. Cellular senes-
cence also appears to cause mitochondrial dysfunction including
loss of membrane potential, decreased respiratory coupling, and
increased ROS production, and these changes were associated with
altered mitophagy (Korolchuk et al, 2017). Mitophagy is the autop-
hagic pathway involved in mitochondrial quality control that
removes damaged mitochondria and regulates mitochondrial
number to match metabolic demand. In mammals, more than 20
proteins have been associated with this process, including PTEN-
induced kinase 1 (PINK1), parkin, serine/threonine-protein kinase
ULK1 (ULK1), BCL2/adenovirus E1B 19 kDa protein-interacting
protein 3-like (BNIP3L/NIX), and serine/threonine-protein kinase
TBK1 (TBK1) (Kerr et al, 2017). Alterations in mitophagy have been
linked to neurodegenerative diseases such as Alzheimer’ disease
(AD) (Fang et al, 2019). Mitophagy also plays a vital role in
neuronal function and survival by maintaining a healthy mitochon-
drial pool and inhibiting neuronal death (Fang et al, 2019). The role
of mitophagy in mitochondrial disease such as those caused by
POLG mutation remains, however, unclear.
In the present study, we generated an experimental model for
POLG-related brain disease using iPSCs reprogrammed from
patient fibroblasts that were differentiated to NSCs. NSCs showed
defective ATP production and increased oxidative stress reflected
by elevated levels of intracellular and mitochondrial ROS. In addi-
tion, we found depletion of mtDNA and loss of mitochondrial
respiratory chain complex I, findings that precisely recapitulate
those from post-mortem tissue studies. Further mechanistic studies
showed that these neural cells had disturbed NAD+ metabolism-
mediated UCP2/SirT1 and increased cellular senescence and
BNIP3-mediated mitophagy, which may contribute to pathological
mechanisms involved in this form of mitochondrial neurodegener-
ation.
Results
Generating iPSCs from patient cells carrying POLG mutations
We generated iPSCs from parental fibroblasts from two patients
carrying POLG mutations, one homozygous for c.2243G>C;
p.W748S (WS5A) and one compound heterozygous c.1399G>A/
c.2243G>C; p.A467T/W748S (CP2A). The clinical symptoms of both
patients included ataxia, peripheral neuropathy, stroke-like
episodes, and PEO (Tzoulis et al, 2006, 2014). Fibroblast lines
Detroit 551, CCD-1079Sk and AG05836 were reprogrammed as
disease-free controls, and two different human embryonic stem
cells, H1 (ESC1) and line 360 (ESC2), were used as internal controls
for iPSC generation and characterization.
All fibroblasts were reprogrammed into iPSCs using a retroviral
or Sendai virus system. Four retrovirus viral particles including
hOCT4, hSOX2, hKLF4, and hcMYC were transduced at an MOI of 5
according to a previously described report (Siller et al, 2016). In
order to account for clonal variation arising during iPSC reprogram-
ming, 2–4 clones from each iPSC line were selected and used for
further investigation (Appendix Table S1).
The Detroit 551 control and patient fibroblast (WS5A, CP2A)
derived iPSCs displayed typical ESC morphology with well-defined
sharp edges and contained tightly packed cells (Fig 1A). No obvious
different appearance was noticed in patient WS5A and CP2A iPSCs
compared to iPSCs generated from Detroit 551 control (Fig 1A). In
order to confirm normal karyotypes for all the reprogrammed iPSC
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lines, G banding analysis was used. We showed that all iPSC lines
presented with the same karyotype as their parental human fibrob-
lasts after reprogramming, with no evidence of chromosomal abnor-
malities (Fig EV1).
Next, we characterized the reprogrammed iPSCs for their
pluripotency using immunostaining and flow cytometry for protein
expression and RT-qPCR analysis for gene expression. Immunos-
taining confirmed that all the iPSCs expressed the specific pluripo-
tent markers POU5F1 and SSEA4 (Fig 1B). RT-qPCR analysis
showed similar mRNA expression levels in terms of LIN28A,
POU5F1, and NANOG in iPSC clones from Detroit 551 control,
WS5A, CP2A, and ESC lines (Fig 1C). In addition, we measured
expression of pluripotent transcription factors POU5F1, NANOG
and pluripotent surface markers SSEA4, TRA-1-60, and TRA-1-81
and quantified these using flow cytometric analysis. Using this
technique, we observed that both the ESC and iPSC lines exhibited
over 98% of POU5F1-positive cells and over 88% of the cells
showed positive staining for SSEA4 (Appendix Fig S1). Interest-
ingly, we detected a lower level of the three pluripotent surface
markers SSEA4 (Fig 1D(a and b)), TRA-1-60 (Fig EV2A(a and b)),
and TRA-1-81 (Fig EV2B(a and b)) in both WS5A and CP2A iPSCs
compared to the two ESC lines and control iPSC line. However, no
changes were observed in the expression of POU5F1 (Fig 1E(a and
b)). We observed a higher expression of NANOG in WS5A
compared to control but not in CP2A lines (Fig EV2C(a and b)). In
addition, clonal variations for the protein level and mRNA expres-
sion were noticed (Figs 1C and D(a), E(a) and EV2A(a), B(a), C
(a)). In order to minimize the phenotypic diversity caused by intr-
aclonal heterogeneity, multiple clones were included in the further
analysis.
Next, we demonstrated that the iPSCs we generated retained the
potential to differentiate into cell types associated with all three
germ layers. We generated hepatocytes (endoderm) with positive
expression of albumin and HNF4A (Fig 2A(a)), cardiomyocytes
(mesoderm) with positive expression of TNNT2 (Fig 2A(b)) and
neurons (ectoderm), specifically dopaminergic neuronal cells with
positive expression of Tyrosine hydroxylase (TH) and MAP2
(Fig 2A(c)).
These data confirm that it is possible to generate patient-
specific iPSCs with POLG mutations by reprogramming of patient
fibroblasts.
POLG iPSCs manifest a partial phenotype
Next, we asked whether iPSCs generated from POLG patients
showed changes in mitochondrial structure or function. Since clonal
variations were detected between ESCs and other iPSC lines during
neuronal differentiation, we compared three homozygous WS5A
iPSC clones and two heterozygous CP2A iPSC clones to four clones
from two different control iPSC lines to investigate mitochondrial
morphology, MMP, and intracellular ATP production. In addition,
we quantified the mtDNA using two approaches (i) indirectly using
flow cytometry and (ii) PCR quantification. ESCs were excluded for
the investigation of the disease-related phenotypes due to the dif-
ference between ESC and other iPSCs lines.
Mitochondrial morphology was analyzed by fluorescence micro-
scopy and mitochondrial activity by flow cytometry. First, we
double-stained cells with MitoTracker Green (MTG) and tetram-
ethylrhodamine ethyl ester (TMRE) (Agnello et al, 2008) and identi-
fied a similar appearance of mitochondrial morphology in both
patient and control iPSCs under confocal microscopy (Fig 2B).
TMRE, a cationic, lipophilic compound, can be used to measure
MMP in live cells as it reversibly accumulates in the highly nega-
tively charged mitochondrial matrix. Thus, membrane potential
can be measured dynamically; release of TMRE after mitochondrial
depolarization and its reuptake after repolarization can be quanti-
fied (Krohn et al, 1999). In order to understand the relationship
between MMP and the volume of mitochondria present in live
cells, we combined MTG and TMRE staining and measured the
relative fluorescence intensity of each by flow cytometry. This ratio
gives a relative measure of MMP independent of mitochondrial
mass that we call specific MMP. To establish this assay, we first
had to evaluate the relationship between MTG and MMP fluores-
cence particularly since MTG fluorescence has been reported to be
both independent of (Doherty & Perl, 2017) and sensitive to MMP
(Pendergrass et al, 2004). We titrated different concentrations of
TMRE against 150 nM MTG in control iPSCs. We saw no signifi-
cant difference in MTG fluorescence in the TMRE concentration
range of 5–100 nM (Appendix Fig S2). Higher TMRE concentrations
(over 100 nM) caused a decrease in MTG fluorescence
(Appendix Fig S2). Thus, we chose 100 nM TMRE and 150 nM
MTG to estimate the specific MMP. Mitochondrial volume
measured by MTG (Fig 2C), total MMP measured by TMRE alone
◀ Figure 1. IPSCs generated from patient fibroblasts carrying homozygous and heterozygous POLG mutations.A Morphology on phase contrast microscopy for parental fibroblast lines (upper panel) and iPSCs (lower panel) from Detroit 551 control, WS5A, and CP2A POLG
patients (scale bars, 50 lm).
B Immunofluorescence staining of stem cell markers POU5F1 (green) and SSEA4 (red): upper panel—Detroit 551 control iPSCs, middle panel—WS5A iPSCs, and lower
panel—CP2A iPSCs (Scale bar, 100 lm). Nuclei are stained with DAPI (blue).
C RT-qPCR quantification of gene expression for LIN28A, NANOG, and POU5F1 for all iPSCs from Detroit 551 control, WS5A, and CP2A POLG patients (n = 7, technical
replicates per line for ESCs; n = 4, technical replicates per clone for control, WS5A, and CP2A iPSCs). The gene expression of the individual clones is assessed with
fold change using the comparative DDCt method by normalizing iPSCs to ESC1.
D, E Flow cytometric quantification of expression level of SSEA4 (D, n = 9, technical replicates per line for ESCs; n = 5, technical replicates per clone for control iPSCs;
n = 3, technical replicates per clone for WS5A iPSCs, n = 8, technical replicates per clone for CP2A iPSCs) and POU5F1 (E, n = 9, technical replicates per line for
ESCs; n = 5, technical replicates per clone for control iPSCs; n = 3, technical replicates per clone for WS5A iPSCs, n = 8, technical replicates per clone for CP2A
iPSCs) for ESCs and iPSCs for both ESC control lines and iPSCs generated from Detroit 551 control, WS5A and CP2A fibroblasts.
Data information: The data presented in C–E were generated from 2 distinct ESC lines, 2 iPSC clones from Detroit 551 control, 3 different clones from WS5A patient, and 2
different clones from CP2A patient iPSCs. Data in D and E are presented as individual (a) and combination as a group (b). Data are presented as mean  SEM for the
number of samples. Mann–Whitney U-test was used for the data presented. Significance is denoted for P values of less than 0.05. ***P < 0.001.
Source data are available online for this figure.
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(Fig 2D), and specific MMP calculated by TMRE/MTG using the
combined assay (Fig 2E) showed no differences between patient
WS5A and CP2A and control iPSCs. We next assessed ATP produc-
tion per cell using a live cell luminescence assay and found signifi-
cantly lower ATP levels in both WS5A and CP2A iPSCs compared
to control iPSCs (Fig 2F).
We investigated mtDNA copy number using two different
approaches: first, with flow cytometry to assess the level of mito-
chondrial transcription factor A (TFAM), which binds mtDNA in
molar quantities and second, using RT-qPCR to quantify the mtDNA
copy number. We performed flow cytometric quantification using
antibodies against TFAM and mitochondrial import receptor subunit
TOM20 (TOMM20), a mitochondrial outer membrane protein, in
order to correlate this to mitochondrial mass. We found no difference
in TOMM20 expression (Fig 2G) and TFAM protein levels corrected
for mitochondrial content in patients versus control (Fig 2H). Lastly,
quantification of mtDNA copy number was performed by RT-qPCR
using the relative method. Mitochondrial and nuclear DNA quanti-
ties were measured amplifying genomic regions of ND1 and APP
genes, respectively. The ratio of mtDNA/nDNA (ND1/APP) was
calculated and showed no difference between iPSC clones in WS5A
and CP2A patient and control (Fig 2I).
Our findings reveal an energy failure with loss of ATP production
in POLG-specific iPSCs, but no change in mitochondrial volume,
membrane potential, or mtDNA level. This suggests that the pluripo-
tent stage is not suitable for modeling mitochondrial disease caused
by POLG mutation.
Neural induction and derivation of neural stem cells carrying
POLG mutations
Primary NSCs serve as a source of different types of neurons and
glial cells in vivo and play a vital role in development, repair, and
the functional modulation of human adult neurogenesis. In addition,
NSC dysfunction may contribute to an assortment of neurological
disorders (Li et al, 2018). We therefore explored whether NSCs
derived from these two patients showed defective mitochondrial
function.
We employed a modified dual SMAD protocol (Fig 3A) to dif-
ferentiate NSCs from both control and patient iPSCs. A three-stage
induction protocol (Fig 3A and B) was applied. Briefly, we utilized
the iPSCs and ESCs with high quality and showing no sign of dif-
ferentiation to initiate the neural induction. After 5 days neural
induction using a chemically defined medium (CDM) supplemented
with SB431542, AMPK inhibitor Compund C and N-acetylcysteine
(NAC), iPSCs (Fig 3B(a)) progressed to a neural epithelial stage
exhibiting clear neural rosette structures (Fig 3B(b)). Neurospheres
were generated by lifting neural epithelium at day 5, and these were
round, well-defined spheres of small to medium size in suspension
culture (Fig 3B(c)). NSCs were then produced by dissociating neuro-
spheres into single cells and then replating in monolayers. NSCs in
monolayers showed a clear neural progenitor appearance (Fig 3B
(d)).
We confirmed the specific stages of neural induction with
immunostaining: iPSCs showed SSEA4 and POU5F1 expression
(Fig 3B(e)); neural epithelial cells showed rosette structures that
uniformly expressed PAX6 and NESTIN (Fig 3B(f)); neurospheres
showed positive NESTIN expression (Fig 3B(g)); and NSCs stained
positively for PAX6 (Fig 3B(h)). Using flow cytometric quan-
tification, we demonstrated that POU5F1 expression decreased
during the induction process, while the neural progenitor markers
NESTIN and PAX6 increased during neural induction over the
5 days (Fig 3C). To minimize intraclonal variation, we included
two different ESC lines, four independent clones from Detroit 551
fibroblasts, one clone from CCD-1079Sk, one clone from control
AG05836, three independent clones from WS5A, and two indepen-
dent clones generated from CP2A fibroblasts. Each line was
subjected to neural induction, on three independent occasions,
generating a total of 33 NSC lines which were used in further
investigations.
Next, we used immunostaining and flow cytometry to investigate
relevant protein markers and RT-qPCR to evaluate gene expression
to characterize the NSC lines. Immunostaining demonstrated that
iPSC-derived NSCs were positive for NESTIN and PAX6 (Fig 3D).
RT-qPCR analysis for neural progenitor markers SOX2, NESTIN, and
PAX6 revealed similar patterns of gene expression for all NSCs
◀ Figure 2. POLG iPSCs manifested a partial phenotype presenting with energy depletion.A Representative confocal images of iPSC lineage-specific differentiation into germ layers of endoderm-derived hepatocytes with positive expression of ALBUMIN
(red) and HNF4A (green) (a) (scale bar, 100 lm), mesodermal-derived cardiomyocytes with positive expression of TNNT2 (red) (b) (scale bar, 100 lm), and
ectodermal-derived dopaminergic neurons with positive expression of TH (green) and MAP2 (red) (c) (scale bar, 10 lm). Nuclei are stained with DAPI (blue).
B Confocal images of mitochondrial morphology for iPSC lines with co-staining of MTG (upper panel) and TMRE (lower panel) (scale bars, 25 lm). Nuclei are stained
with DAPI (blue).
C–E Flow cytometric analysis of iPSCs generated from Detroit 551, WS5A, and CP2A fibroblasts for mitochondrial volume (MTG) (C, n = 6, technical replicates per clone
for control and CP2A; n = 5, technical replicates per clone for WS5A), total MMP (TMRE) (D, n = 6, technical replicates per clone for control and CP2A; n = 5,
technical replicates per clone for WS5A) and specific MMP (E, n = 6, technical replicates per clone for control and CP2A; n = 5, technical replicates per clone for
WS5A) calculated by dividing median fluorescence intensity (MFI) for total TMRE expression by MTG.
F Intracellular ATP production in iPSCs generated from Detroit 551, WS5A, and CP2A fibroblasts (n = 3, technical replicates per clone for control and WS5A; n = 4,
technical replicates per clone for CP2A).
G, H Flow cytometric analysis of TOMM20 expression level (G, n = 4, technical replicates per clone) and specific TFAM level (total TFAM/TOMM20) (H, n = 4, technical
replicates per clone).
I Relative mtDNA copy number in Detroit 551, WS5A and CP2A iPSCs by RT-qPCR analysis using ND1 and APP (n = 5, technical replicates per clone for control; n = 5,
technical replicates per clone for WS5A and CP2A). Values are presented as Log2 of the ratio between the expression values of ND1 in relation to APP.
Data information: The data presented in C–I were generated from 2 different iPSC clones from Detroit 551 control, 3 different clones from WS5A patient iPSCs, and 2
different clones from CP2A patient iPSCs. Data are presented as mean  SEM for the number of samples. Mann–Whitney U-test was used for the data presented in C
and E. Two-sided Student’s t-test was used for the data presented in D and F–I. Significance is denoted for P values of less than 0.05. ***P < 0.001.
Source data are available online for this figure.
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(Fig 4A). Since quantification using immunostaining is challenging,
we performed flow cytometry to analyze the purity of our NSC cell
populations. All NSCs showed positive protein expression of NSC
markers PAX6 (Fig 4B) and NESTIN (Fig 4C), with over 94% of the
population positive for NESTIN (Appendix Fig S3). In addition, our
data showed that the protein expression level for PAX6 (Fig EV3A)
exhibited a peak on passage 7 and dropped afterward, and the
pluripotency marker POU5F1 (Fig EV3B) remained unchanged
during long-term cultivation. Thus, all the NSCs used for further
investigation were limited to passages 4–9.
We confirmed that the NSCs generated from patients main-
tained the same POLG gene profile of the parental cells by demon-
strating that they retained the same mutation as the original
fibroblasts (Fig 4D). Thereafter, we showed that these NSCs had
the potential to differentiate into glial subtypes and neurons,
including astrocytes which expressed glial fibrillary acidic protein
(GFAP, Fig 4E(a)), S100 calcium-binding protein b (S100b)
(Appendix Fig S4), excitatory amino acid transporter 1 (EAAT1),
and glutamine synthetase (Appendix Fig S5); oligodendrocytes via
expression of galactocerebroside (GALC, Fig 4E(b)), oligodendro-
cyte transcription factor (OLIG2) and myelin basic protein (MBP)
(Appendix Fig S6), and dopaminergic (DA) neurons which were
positive for TH and tubulin beta III (TUJ1) (Fig 4E(c)).
These findings indicate that it is possible to generate patient-
specific, POLG-mutated NSCs with reasonable purity and efficiency.
We also confirm that our iPSC-derived NSCs faithfully retained the
original genotype (Ma et al, 2015; Kang et al, 2016) and carried the
sequencing with the relevant POLG exons.
POLG NSCs showed a greater impairment of mitochondrial
function compared to iPSCs and parental fibroblasts
We applied the same experimental approaches as described above to
investigate mitochondrial function in NSCs. We compared a panel of
different NSCs generated from three homozygous WS5A iPSC clones
and two heterozygous CP2A iPSC clones to three clones from Detroit
551 iPSCs, one clone from CRL2097, and one clone from AG05836
control, to investigate mitochondrial morphology, MMP, and intra-
cellular ATP production. In addition, we assessed the original patient
fibroblast lines to determine whether a phenotype was present.
We assessed mitochondrial morphology by transmission electron
microscopy and found similar morphology in both patient and
control NSCs, displaying normal and well-developed cristae
(Fig 5A).
Using the TMRE/MTG double staining approach described
above, we found that mitochondrial volume was less in WS5A, but
similar in CP2A NSCs compared to control lines (Fig 5B). While the
total MMP (Fig 5C) appeared decreased in mutant NSCs as
compared to control, no significant difference was detected in the
specific MMP level, i.e. MMP per mitochondrial volume (total
TMRE/MTG) (Fig 5D). In fibroblasts, similar mitochondrial volumes
were found in mutant and control cells based on MTG level
(Fig 5F). However, a significantly increased total (Fig 5G) and speci-
fic MMP (Fig 5H) was seen in fibroblasts from both WS5A and
CP2A mutants versus control lines.
Direct measurement of intercellular ATP production revealed a
significant defect in both WS5A and CP2A NSCs compared to
control (Fig 5E). Interestingly, this was also seen in the parental
fibroblasts (Fig 5I) and iPSCs (Fig 2F). Fibroblasts, however,
appeared capable of maintaining and indeed increasing their
membrane potential (Lorenz et al, 2017), possibly by hyperpolariza-
tion, while NSCs did not.
Our data indicate a cell lineage/tissue specificity in response to
POLG mutation. Energy depletion is seen in both NSCs and fibrob-
lasts, but the effect on MMP differed. This differential response
suggests that neurons are selectively vulnerable to the mitochon-
drial changes induced by POLG mutation.
POLG NSCs manifest mtDNA depletion, but not mtDNA deletion
We assessed mtDNA both qualitatively and quantitatively. As previ-
ously, we used both flow cytometric analysis of TFAM and qPCR.
We detected a significant decrease of specific TFAM protein level
(TFAM/TOMM20) in both WS5A and CP2A NSCs compared to
control (Fig 6B), whereas no changes were observed at TOMM20
expression level (Fig 6A). Quantification based on RT-qPCR
measurements of the ND1/APP ratio also revealed a significant
reduction of mtDNA copy number in patient WS5A and CP2A NSCs
(Fig 6C). In contrast, TOMM20 (Fig 6D) and TFAM levels (Fig 6E),
as well as mtDNA copy number (Fig 6F), were not significantly
changed in patient fibroblasts. These findings further demonstrate
the differential response between patient NSCs (Fig 6A–C), iPSCs
(Fig 2G–I), and parental fibroblasts (Fig 6D–F). The fact that
mtDNA depletion arises in neural lineage indicates that NSCs are a
◀ Figure 3. Validation of patient-specific NSCs.A Schematic of dual differentiation and seeding paradigm for NSCs via the dual SMAD protocol.
B Representative phase contrast images (upper panel) and immunostaining for specific stages during neural induction from iPSCs to NSCs. Upper panel displays the
morphology in culture of different cell types during neural induction to NSCs from iPSCs including iPSCs (a); neuroepithelium with rosette-like structures (b);
neurospheres with defined round shapes in suspension culture (c); and NSCs in monolayers (d) (scale bars, 50 lm). Lower panel demonstrates the representative
phase contrast images for the immunostaining corresponding to the specific stages in the upper panel: iPSCs with positive staining of SSEA4 (red) and POU5F1
(green) (e) (scale bar, 50 lm); neuroepithelium with rosette-like structures with positive staining of PAX6 (green) and NESTIN (red) (f) (scale bar, 50 lm); neurospheres
with positive staining of NESTIN (red) (g) (scale bar, 100 lm); NSCs with positive staining of PAX6 (green) (h) (scale bar, 50 lm).
C Flow cytometric assessment of stemness marker POU5F1 and NSC markers NESTIN and PAX6 during neural induction from day 0 to day 5 (n = 3, technical replicates).
D Representative images of the immunofluorescent labeling for NSC markers SOX2 (green) and NESTIN (red) (scale bar, 25 lm) from Detroit 551 control iPSC-derived
NSCs. Nuclei are stained with DAPI (blue).
Data information: The data presented in C were generated from one iPSC clones (clone 1) from Detroit 551 control. Data are presented as mean  SEM for the number
of samples. Mann–Whitney U-test was used to test the significant difference in the expressions of days 1–5 compared to day 0. Significance is denoted for P values of
less than 0.05. *P < 0.05; **P < 0.01.
Source data are available online for this figure.
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relevant model system for mtDNA-associated disease with POLG
mutation.
Since we previously identified mtDNA deletions in post-mortem
neurons from patients (Tzoulis et al, 2014), we used long range
PCR to investigate whether qualitative mtDNA damage also
occurred in NSCs. Deletions were not detectable in the mtDNA of
patient NSCs and nor were they found in the parental fibroblasts
(Fig 6G). Thus, the accumulation of mtDNA deletions appears time
dependent, both in aging tissues (Kazachkova et al, 2013) and in
neurons of POLG patients (Tzoulis et al, 2014).
These findings indicate that NSCs but not fibroblasts or iPSC
faithfully replicate the mtDNA depletion found in post-mortem
neurons. Deletions of mtDNA, which only accumulate slowly over
time, were not found.
POLG dopaminergic (DA) neurons confirm mtDNA findings
in NSCs
As DA neurons of the substantia nigra were one of the most affected
cell types in POLG disease (Tzoulis et al, 2014), we generated this
specific neuronal type to investigate whether we could replicate the
pathological findings seen in NSCs.
We applied DA neuron differentiation based on the dual SMAD
method with the addition of FGF-8 and Sonic hedgehog (SHH)
agonist purmorphamine (PM), modified from a previous report
(Stacpoole et al, 2011). This procedure included, Phase I: the first
stage of differentiation from stem cells to neural rosette-like colo-
nies, and the second stage of differentiation from neural rosette-
like colonies to neurospheres by dual inhibition of SMAD signal-
ing with SB431542 and dorsomorphin/Compound C. Phase II and
III: caudalization of neurospheres with addition of FGF-8 and
further ventralization to dopaminergic progenitors using the
combination of FGF-8 and the SHH agonist PM. Phase IV: DA
neuron maturation from DA progenitors by adding BDNF and
GDNF. Using this protocol, both control and POLG mutant iPSCs
efficiently differentiated into mature DA neurons as shown by
both TH and MAP2 expression (Fig 6H), and the yield of TH-posi-
tive neurons was over 97% in both control and POLG cultures
(Fig 6I).
We then investigated alterations of TFAM level and mtDNA copy
number in both WS5A and CP2A DA neurons. We found that
mutant DA neurons displayed similar defects to those seen in NSCs
(Fig 6B and C), with both lower TFAM level (Fig 6J) and mtDNA
copy number (Fig 6K) than control DA neurons.
Our findings confirm that different cell types respond differently
to the same bioenergetic challenge. However, considering neurons
are difficult to acquire and display limited expansion potential, it
would be preferential to use NSCs as they are feasible to expand,
bank, and can potentially enable high-throughput drug screening.
Since we found that NSCs manifest POLG disease phenotypes, NSCs
were considered as a precise and reliable cell type and applied for
further studies of disease mechanisms.
Respiratory chain complex I loss, NAD+/NADH redox changes and
ROS excess occur in POLG NSCs, but not iPSCs
We showed previously that respiratory chain complex I was lost
in POLG affected frontal and cerebellar neurons (Tzoulis et al,
2014), and we confirmed these findings in this current study. We
studied occipital neurons collected from fresh frozen brain tissue
taken from patients with POLG mutations (n = 5) and controls
(n = 5). The POLG mutations were as follows: A467T/G303R (AL-
1B); A467T/A467T (AT-1A); A467T/A467T (AT-2A); W748S/
W748S (WS-10A), and W748S/W748S (WS-3A). In agreement
with our previous study, immunohistochemistry demonstrated
clear complex I deficiency in occipital neurons of POLG patients
(Fig 7A(a–c)). Further, relative quantification of mtDNA from
microdissected occipital neurons showed significantly decreased
mtDNA copy number in the patient neurons compared to controls
(Fig 7A(d)).
We then investigated whether this also occurred in POLG cells.
To quantify complex I level, we used Anti-NDUFB10, the same anti-
body as was used in post-mortem studies. Co-staining with
TOMM20 was used to correlate complex level to mitochondrial
mass. We found a similar level of complex I in both patient and
control iPSCs (Fig 7F). Levels of complex II (Fig 7G) and IV
(Fig 7H) were also similar in iPSCs. In NSCs, however, we observed
a significant decrease in mitochondrial complex I assessed by both
immunostaining (Fig 7B) and flow cytometry (Fig 7C). This was not
seen in either iPSCs (Fig 7F) or fibroblasts (Fig 7I). Although no
significant changes in mitochondrial complex II (Fig 7D) or IV subu-
nits (Fig 7E) were found in mutant NSCs or fibroblasts (Fig 7J and
K) as compared to control lines, lower complex IV subunit was
found in WS5A NSCs compared to control (Fig 7E). These data
◀ Figure 4. NSCs retained the original genotype and sequence.A Quantification of gene expression for NSC markers PAX6, NESTIN, and SOX2 for all NSCs from RT-qPCR analysis. The expression of the neural stem cell markers is
assessed with fold change using the comparative DDCt method by normalizing NSCs to iPSCs (n = 3, technical replicates per ESC line or iPSC clone).
B, C Quantification of protein expression level for PAX6 (B, n = 6, technical replicates per line for ESCs; n = 7, technical replicates per clone for control; n = 8, technical
replicates per clone for WS5A; n = 9, technical replicates per clone for CP2A) and NESTIN (C, n = 6, technical replicates per line for ESCs; n = 7, technical replicates
per clone for control; n = 8, technical replicates per clone for WS5A; n = 9, technical replicates per clone for CP2A) for iPSC-derived NSCs using flow cytometry.
D Sequencing chromatogram showing the homozygous c.2243G>C variation in POLG in WS5A iPSC-derived NSCs and the heterozygous c.1399G>A and c.2243G>C
variation in POLG in CP2A iPSC-derived NSCs.
E Representative confocal images showing glial and neuronal lineages derived from NSCs. (a) Immunostaining of NSC-derived astrocytes with GFAP (red) staining
(scale bar, 50 lm). (b) Immunostaining of oligodendrocytes showing GALC (red)-positive labeling (scale bar, 50 lm). (c) Dopaminergic neurons showing TH (green)
and TUJ1 (red)-positive staining (scale bar, 25 lm). Nuclei are stained with DAPI (blue).
Data information: The data points in A–C represent NSCs generated from 2 ESC lines, 3 different control iPSCs including 2 different clones from Detroit 551 control, one
clone from control AG05836, 3 different clones from WS5A patient, and 2 different clones from CP2A patient iPSCs. Data are presented as mean  SEM for the number of
samples.
Source data are available online for this figure.
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indicate that, similar to both POLG patient tissues, complex I defect
is present in NSCs.
Complex I function is essential for the re-oxidization of NADH
and maintenance of the NAD+/NADH ratio, which is an important
indicator of redox status and major modulator of intermediary meta-
bolism (Houtkooper et al, 2010). To investigate the effect of POLG
mutation on NAD+ metabolism, we measured both NAD+ and
NADH levels using liquid chromatography–mass spectrometry (LC-
MS). As expected, we found a significant decrease in the NAD+/
NADH ratio in both patient NSCs compared with control (Fig 8A).
While the levels of NAD+ and NADH varied in the patient NSCs
(Fig 8B and C), the ratio showed disturbed NAD+ homeostasis in
both. To confirm these findings, we performed colorimetric analysis
using a commercial NAD+/NADH assay. Similar to the findings
from LC-MS, we found a significant decrease of NAD+/NADH ratio
in both patient NSCs versus control (Appendix Fig S8). However,
we found an increase in the NAD+/NADH ratio (Fig 8D) and
reduced level of NAD+ (Fig 8E) and NADH (Fig 8F) in both patient
iPSCs compared with control, though only the CP2A line reached
significance (Fig 8D–F).
The mitochondrial respiratory chain is considered to be a major
source of intracellular ROS, and the dysfunction of complex I is
particularly implicated in excess ROS production (Hayashi & Corto-
passi, 2015), which potentially can damage both mitochondria and
mtDNA (Cui et al, 2012). To investigate whether the presence of
POLG mutation led to increased ROS production, we used dual stain-
ing with 20,70-dichlorodihydrofluorescein diacetate (DCFDA) and
MitoTracker Deep Red (MTDR). We found no major differences in
ROS production (DCFDA) in patient WS5A and CP2A iPSCs
compared to controls (Fig EV4A). To ensure that this reflected the
mitochondrial mass in each cell type, we divided total ROS by a
measure of mitochondrial mass (MTDR) to give specific ROS and
again found no difference between patient and control iPSCs
(Fig EV4B). Interestingly, a trend toward reduced total (Fig EV4C)
and specific ROS level (Fig EV4D) was detected in patient fibrob-
lasts. In contrast, both total ROS (Fig EV4E) and specific ROS
(Fig 8G), i.e., the ratio of ROS to mitochondrial volume defined by
MTDR, appeared significantly higher in mutant NSCs compared to
control, indicating the potential for oxidative damage in mutant
NSCs. To confirm that the increased ROS was of mitochondrial
origin, we used the ROS-sensitive fluorescent dye MitoSox and
quantified both total and the ratio of ROS to mitochondrial volume
defined by MTG, i.e., specific ROS. Both patient NSCs showed a
significant increase in the mean intensity of MitoSox fluorescence at
specific level (Fig 8H), suggesting the high ROS production gener-
ated from mitochondria itself. However, the total level of mitochon-
drial ROS was lower in WS5A patient but higher in CP2A patient
compared to control (Fig EV4F).
These data suggest that complex I loss has functional conse-
quences. The disturbance of NAD+ homeostasis will have major
implications for neurons that are heavily dependent on glucose
metabolism and thus reoxidation of NADH generated by the citric
acid cycle. Increased ROS production leads potentially to a more
indiscriminate damage. Both consequences are likely to contribute
to the pathological mechanism of POLG-related diseases.
UCP2/SirT1-regulated cellular senescence and BNIP3 pathway-
mediated mitophagy are involved in the pathogenesis of
neuronal POLG diseases
In view of the changes in NAD+ metabolism and the known link
between mitochondrial dysfunction with increased ROS production
and aging (Fang et al, 2019), we investigated cellular senescence
and mitophagy in our NSCs. We performed staining of b-galactosi-
dase and flow cytometric measurements of cellular senescence
marker p16INK4. We observed significantly increased activity for b-
galactosidase in both patient WS5A and CP2A NSCs compared to
control NSCs (Fig 8I and J). This finding was further corroborated
with flow cytometry against p16INK4 (Fig EV5).
Next, we investigated the molecular pathways linked to initiating
the process of senescence. Previous studies have shown that over-
production of mitochondrial uncoupler protein 2 (UCP2) irreversibly
reduces the MMP and induced a senescent-like morphology, leading
to irreversible metabolic changes, loss of cellular ATP, and high
ROS (Nishio & Ma, 2016). Sirtuin 1 (SirT1) is the most conserved
mammalian NAD+-dependent protein deacetylase and is increas-
ingly recognized as a crucial regulator of a variety of cellular
processes, including energy metabolism, stress response, and senes-
cence (Li, 2013). In addition, SirT1 has been shown to repress the
UCP2 gene by binding directly to the UCP2 promoter (Bordone et al,
2006). To investigate a possible pathogenic role for UCP2 and SirT1
in POLG-induced senescence, we examined the expression of UCP2
◀ Figure 5. POLG NSCs exhibited impaired mitochondrial function, which was partly presented in fibroblasts.A Representative transmission electron microscopy images of mitochondrial structures in Detroit 551 control, WS5A, and CP2A NSCs (scale bar, 400 nm).
B–D Flow cytometric analysis of mitochondrial volume (MTG) (B, n = 5, technical replicates per clone), total MMP (TMRE) (C, n = 5, technical replicates per clone), and
specific MMP (D, n = 5, technical replicates per clone), calculated by dividing median fluorescence intensity (MFI) for total TMRE expression by MTG in NSCs
generated from control lines, WS5A, and CP2A iPSCs.
E Intracellular ATP production in NSCs (n = 3, technical replicates per clone).
F–H Flow cytometric analysis of mitochondrial volume (MTG) (F, n = 6, technical replicates for control; n = 5, technical replicates for WS5A and CP2A), total MMP
(TMRE) (G, n = 5, technical replicates for control; n = 4, technical replicates for WS5A and CP2A), and specific MMP (TMRE/MTG) (H, n = 5, technical replicates for
control; n = 4, technical replicates for WS5A and CP2A) in Detroit 551, WS5A, and CP2A fibroblasts.
I Intracellular ATP production in Detroit 551, WS5A, and CP2A fibroblasts (n = 6, technical replicates for control; n = 3, technical replicates for WS5A and CP2A).
Data information: The data points in B–D represent NSCs generated from 5 different control iPSCs including 3 different clones from Detroit 551 control, one clone from
CCD-1079Sk, one clone from control AG05836, 3 different clones from WS5A patient iPSCs, and 2 different clones from CP2A patient iPSCs. The data points in E represent
NSCs derived 3 different clones from Detroit 551, 3 different clones from WS5A, and 2 different clones from CP2A iPSCs. Data are presented as mean  SEM for the
number of samples. Mann–Whitney U-test was used for the data presented in B and C. Two-sided Student’s t-test was used for the data presented in D–I. Significance is
denoted for P values of less than 0.05. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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and the phosphorylated phospho-SirT1 (Ser47) by western blot. We
found upregulation of UCP2 expression and reduced phosphorylated
SirT1 in both WS5A and CP2A NSCs compared with control (Fig 8K
and L(a and c)). These data suggested that decreased SirT1 activity
and increased UCP2 expression might be involved in cellular senes-
cence observed in POLG mutation.
Mitophagy/autophagy appeared able to both promote and inhibit
senescence and senescence-associated phenotypes (Korolchuk et al,
2017). To investigate whether an activation of mitophagy was
involved in POLG-related disorders, we studied the mitophagy-
related proteins PINK1, Parkin, BNIP3, and LC3B using western
blotting. Immunoblotting analysis showed an increased level of the
autophagosome marker microtubule-associated protein 1 light chain
3b (LC3B-II) with increased ratio of LCBII/LC3BI in CP2A NSCs
indicating autophagy activation (Fig 8K and L(b)). PINK1 and
Parkin expression were similar to the control group (Fig 8K and L(d
and e)), while BNIP3 accumulation was also observed in CP2A, but
not WS5A (Fig 8K and L(f)). Our data showed that POLG mutation
increase cellular senescence and is associated with increased mito-
phagy.
Our data suggests that POLG mutation can induce cellular senes-
cence and that this may be modulated via upregulation of UCP2.
We also find that mitophagy is an active component of neuronal
POLG pathogenesis, particularly in the compound heterozygote
model.
Discussion
Despite the presence of mitochondria in most cells, mitochondrial
disorders manifest strikingly different tissue involvement (Chinnery,
2015). POLG-related disorders, for example, show major involve-
ment of the nervous system and liver. Modeling brain diseases have
been hampered by the limited availability of human tissue and lack
of faithful disease models. These present major obstacles to our
understanding of disease mechanisms and the development of effec-
tive treatments. Reprogramming of patient cells combined with their
differentiation to the affected cell type has revolutionized the field
(Kanherkar et al, 2014; Tabar & Studer, 2014). Here, we repro-
grammed patient fibroblasts carrying the two common POLG muta-
tions (c.2243G>C; p.W748S and c.1399G>A; p.A467T) to iPSCs and
then differentiated these to NSCs. We found that patient-specific
NSCs replicated the findings of mtDNA depletion and complex I
deficiency identified in post-mortem tissues. While others have
generated iPSCs from patients with POLG mutations (Zurita et al,
2016; Chumarina et al, 2019) or investigated valproate toxicity in
iPSC-derived POLG patient hepatocytes (Li et al, 2015), we believe
our study is the first to confirm that the pathological changes seen
in post-mortem studies are faithfully replicated in iPSC-derived
NSCs. More importantly, using iPSC-derived NSCs we were able to
identify cellular and molecular mechanisms involved in the disease
process including the overproduction of ROS associated with
suppressed complex I-driven respiration and defective NAD+ meta-
bolism leading to cellular senescence via UCP2 upregulation and
SirT1 downregulation pathway and mitophagy activation. These
findings provided compelling evidence of the multiple cellular and
molecular mechanisms contributing to the decline of neuron pool in
POLG-related diseases and open the way for the development of
novel diagnostic and therapeutic interventions.
In the present study, we found that iPSCs harboring POLG muta-
tions appeared to be able to maintain their MMP, mitochondrial
mass, and mtDNA replication at similar levels to control. They also
appeared capable of regulating their ROS homeostasis. This
suggested either that the mutant phenotypes were rescued at this
stage, as was suggested by an earlier study of iPSCs with mtDNA
mutations (Ma et al, 2015), or that, similar to fibroblasts, these cells
derived proportionally more of their energy from glycolysis and
maintained ROS levels by lowered respiratory chain activity.
However, both mutated iPSCs and fibroblasts showed significantly
lower ATP levels. In addition, ATP depletion was associated with
◀ Figure 6. POLG NSCs exhibited decreased TFAM level and mtDNA depletion, but not mtDNA deletion, consistent with iPSC-derived DA neurons.A, B Flow cytometric analysis of TOMM20 (A, n = 3, technical replicates per clone for control; n = 4, technical replicates per clone for WS5A and CP2A) and TFAM
protein expression (B, n = 3, technical replicates per clone for control and CP2A; n = 5, technical replicates per clone for WS5A) in NSCs. Expressed as specific TFAM
level (total TFAM/TOMM20).
C Relative mtDNA copy number analyzed by RT-qPCR using primers and fluorogenic probes for regions of ND1 and nuclear gene APP in all NSCs (n = 4, technical
replicates per clone for control; n = 5, technical replicates per clone for WS5A; n = 7, technical replicates per clone for CP2A).
D, E Flow cytometric analysis of TOMM20 expression level (D, n = 4, technical replicates per clone) and TFAM protein expression (E, n = 4, technical replicates for
control and WS5A; n = 5, technical replicates for CP2A) in fibroblasts. Expressed as specific TFAM level (total TFAM/TOMM20).
F Relative mtDNA copy number analyzed by RT-qPCR for regions of ND1 and nuclear gene APP in fibroblasts (n = 3, technical replicates for control; n = 4, technical
replicates for WS5A and CP2A).
G Long-PCR for detection of mtDNA deletions in NSCs and their parental fibroblasts from WS5A and CP2A patients.
H Representative images of confocal microscopy with immunofluorescence labeling of DA neuron-specific marker TH (green) and neuron-specific marker MAP2 (red)
for iPSC-derived DA neurons (scale bars, 25 lm). Nuclei are stained with DAPI (blue).
I Histogram of the positive cell population stained with DA marker TH in iPSC-derived DA neurons using flow cytometric analysis.
J Flow cytometric measurement of specific TFAM level (total TFAM/TOMM20) in iPSC-derived DA neurons from Detroit 551 control, WS5A, and CP2A POLG patients
(n = 8, technical replicates per clone for control; n = 5, technical replicates per clone for WS5A; n = 4, technical replicates per clone for CP2A).
K Relative mtDNA copy number analyzed by RT-qPCR for regions of ND1 and nuclear gene APP in all iPSC-derived DA neurons (n = 3, technical replicates per clone).
Data information: The data points in A, B represent NSCs generated from 3 different control iPSCs including 2 different clones from Detroit 551 control, 1 clone from
control AG05836, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs. Data points in C represent NSCs from 5 different controls, including 3 clones
from Detroit 551 control, 1 clone from control AG05836, 1 clone from control CCD-1079Sk, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs. The
data points in J and K represent DA neurons generated from 3 clones from Detroit 551 control, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs.
Data are presented as mean  SEM for the number of samples. Mann–Whitney U-test was used for the data presented in A and J. Two-sided Student’s t-test was used
for the data presented in B–F and K. Significance is denoted for P values of less than 0.05. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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mitochondrial hyperpolarization in fibroblasts. These findings are
similar to those observed in another stem cell model of mitochon-
drial disease (Lorenz et al, 2017) and suggest either that these cells
compensated for lower ATP production by reversing the proton flow
in the F1Fo ATPase (Abramov et al, 2010) or the presence of other
mechanisms such as downregulating oxygen consumption through
complex II (Forkink et al, 2014) are active.
We successfully generated patient-specific NSCs and DA
neurons. Combined with neurons being difficult to acquire and
display limited expansion potential, NSCs provide a powerful tool to
unravel disease mechanism and, potentially, enable high-
throughput drug screening. Further, one can perform assays of mito-
chondrial function in “live cells”. From our previous (Tzoulis et al,
2014) and present studies in NSCs, we observed the following
potential mechanisms. Confirmation of the loss of complex I in
neurons from the occipital cortex and verification of this at the early
progenitor stage and in patterned DA neurons. A key finding from
our patient studies (Tzoulis et al, 2014) was mtDNA depletion was
present in neurons from infants under 1 year of age, and this was
also observed in our patient NSCs. Depletion of mtDNA was not,
however, present in patient fibroblasts or the derived iPSCs. Inter-
estingly, while depletion was clearly detected by qRT-PCR, we also
observed lowered mtDNA levels using an indirect method based on
flow cytometric measurement of TFAM. Methodologically, this is of
major interest as it suggested that we could use this in live cells as a
surrogate measure of mtDNA level. The presence of mtDNA deple-
tion did not appear to impair cell growth; however, unlike the situa-
tion in patients, we did not expose our cells to any form of stress.
Deletions of mtDNA were not observed in any of the above cell
types, suggesting that these were generated over time in post mitotic
tissues. The lack of qualitative mtDNA damage supported our earlier
conclusion that these changes were cumulative and representative
of “accelerated aging”.
Since complex I is a major site of ROS production, it has been
suggested that loss of this complex is part of a response aimed at
reducing the production of these damaging species (Palin et al,
2013). Further, Pryde et al (2016) provided evidence that complex I
degradation was mediated through protease-dependent inactivation.
Interestingly, complex I loss was found to affect the whole brain in
Parkinson’s disease (Flones et al, 2018), not just the substantia
nigra (Palin et al, 2013; Flones et al, 2018), supporting the view that
loss of this complex was not itself the cause of neuronal loss, but a
secondary event. Irrespective of whether neuronal complex I defi-
ciency and elevated ROS are pathological events or a compensatory
response, they are clearly important features associated with the
POLG disease process in neurons and changes in level of these may
be useful for monitoring treatment or other interventions. Here, we
found a clear overproduction of ROS. It was attractive to postulate a
causal relationship between these findings. The relationship
between ROS and cell death and increased ROS and complex I loss
remains unclear. Abrupt increases in ROS levels, i.e., above a physi-
ological threshold, may be harmful and may among other events
trigger cell death (Davila & Torres-Aleman, 2008). Oxidative stress
has been linked to many neurodegenerative diseases, including
Alzheimer’s (Leuner et al, 2012) and Parkinson’s (Schapira, 2008),
but its role in mitochondrial disease remains unclear.
Cellular senescence is as a complex stress response by which
proliferative cells lose the ability to divide and enter cell cycle arrest.
Mounting evidence also showed accumulation of senescent cells
with age, a process that may contribute to age-related phenotypes
and pathologies (Byun et al, 2015). Dysfunctional mitochondria can
induce cellular senescence both in in vitro culture (Moiseeva et al,
2009) and in vivo (Kang et al, 2013; Wiley et al, 2016). Some stud-
ies have implicated mitochondrial ROS in this process since ROS are
capable of damaging nuclear DNA and thus activating a DNA
damage response to induce senescence (Moiseeva et al, 2009).
Redox changes, reflected by a lower NAD+/NADH ratio, were also
likely to induce a senescence arrest (Lee et al, 2012). We showed
that dysfunctional mitochondria due to POLG mutation could drive
ROS overproduction and lower the NAD+/NADH ratio, raising the
possibility that both were involved in generating the senescence
response in POLG NSCs.
A previous study reported that the NAD+-dependent deacetylase
SirT1 played an important role in the acceleration of cellular
◀ Figure 7. POLG mutations induced defects in respiratory chain complex I.A Complex I immunohistochemistry in the occipital cortex of a neurologically healthy control (a) and two patients with POLG disease (b and c) (Scale bar, 20 lm).
Patients have numerous complex I-negative neurons (examples marked by arrows). (d) mtDNA relative quantification in microdissected neurons from the occipital
cortex of patients with POLG diseases (n = 5) and neurologically healthy controls (n = 5). Each point represents the mean value of three technical replicates from a
pooled sample of 10 neurons. For the purposes of comparison, a control sample has been arbitrarily set to one. The medians of the two groups are compared by
Mann–Whitney U-test. Data are presented as mean (horizontal bars)  SEM (vertical bars).
B Representative confocal images of immunostaining for mitochondrial complex I subunit NDUFB10 (green) and TOMM20 (red) in control, WS5A, and CP2A NSCs
(scale bars, 50 lm). Nuclei are stained with DAPI (blue).
C–E Flow cytometric measurements of mitochondrial complex I (C, n = 4, technical replicates per clone), II (D, n = 3, technical replicates per clone for control; n = 4,
technical replicates per clone for WS5A and CP2A) and IV (E, n = 3, technical replicates per clone for control and CP2A; n = 4, technical replicates per clone for
WS5A) protein level in iPSC-derived NSCs. Expressed as specific complex I, II, and IV level (total complex I, II, IV level/TOMM20).
F–H Flow cytometric measurements of mitochondrial complex I (F, n = 4, technical replicates per clone), II (G, n = 4, technical replicates per clone) and IV (H, n = 4,
technical replicates per clone) protein level in iPSCs. Expressed as specific complex I, II, and IV level.
I–K Flow cytometric measurements of mitochondrial complex I (I, n = 4, technical replicates), II (J, n = 4, technical replicates), and IV (K, n = 4, technical replicates)
protein level in parental fibroblasts expressed as specific complex I, II, and IV level.
Data information: The data points in C represent NSCs generated from 5 different controls, including 3 clones from Detroit 551 control, 1 clone from control AG05836, 1
clone from control CCD-1079Sk, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs. The data points in D, E represent NSCs generated from 3 clones
from Detroit 551 control, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs. The data points in F–H represent 2 clones from Detroit 551 iPSCs, 3
clones from WS5A patient iPSCs, and 2 clones for CP2A iPSCs. Data are presented as mean  SEM for the number of samples. Mann–Whitney U-test was used for the
data presented in F and J. Two-sided Student’s t-test was used for the data presented in C–E, G–I and K. Significance is denoted for P values of less than 0.05. *P < 0.05;
***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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senescence induced by oxidative stress via p53 acetylation (Furu-
kawa et al, 2007). Further, it has been reported that SirT1 represses
expression of the UCP2 gene by binding directly to the UCP2
promoter (Amat et al, 2007). UCP2, a mitochondrial transporter
present in the inner mitochondrial membrane, plays an important
role in uncoupling oxidative phosphorylation and decreasing mito-
chondrial O2 consumption by regulating the MMP. UCP2 overpro-
duction following total loss of cellular ATP was found to induce
irreversible metabolic changes and senescent-like morphology
(Nishio & Ma, 2016). Here, we showed that SirT1 signaling
decreased, while UCP2 signaling increased in POLG-mutated cells,
suggesting that senescence may indeed contribute to neuronal loss
in POLG-related diseases.
Mitophagy plays a role in maintaining mitochondrial health
throughout life and preventing age-related disease. Mitophagy can
either specifically eliminate damaged or dysfunctional mitochondria
or clear all mitochondria during specialized developmental stages.
Accumulating evidence suggests that mitophagy is associated with
neurodegenerative disorders, including Parkinson’s (Ryan et al,
2015), Huntington’s (Khalil et al, 2015), and Alzheimer’s disease
(Fang et al, 2019). Recent progress in mitophagy studies revealed
that mitochondrial priming was mediated either by the PINK1-
Parkin signaling pathway (Shiba-Fukushima et al, 2012) or by the
mitophagic receptors Nix (Vo et al, 2019) and BNIP3 (Tang et al,
2019). Our finding on the upregulation of BNIP3 protein levels and
occurrence of mitochondrial autophagosomes in NSCs with
heterozygous POLG mutations suggested active degradation through
mitophagy. This evidence suggested that BNIP3-mediated autop-
hagy/mitophagy may be involved in POLG-related pathogenesis.
There are two technical questions pertaining to our study that
require discussion. Firstly, isogenic controls were not used. We
recognize that the current state of the art is to compare patient
samples to gene-corrected isogenic controls, usually made by
CRISPR-based gene editing. In our studies, however, we considered
that the use of multiple, age-matched controls (n = 5) remained a
viable alternative. This choice was, in part, driven by the presence
of a compound heterozygous patient (CP2A patient). Further, we
would point out that many studies still use age/gender-matched
controls from healthy individuals as disease comparators as exem-
plified by the recent study of another POLG mutation, p.Q811R
(Chumarina et al, 2019). Nevertheless, in cases of loss of function
mutations and to minimize background-specific confounding
factors, we agree that gene-corrected isogenic controls or a well-
executed rescue experiment should be conducted.
Secondly, we used retroviral reprogramming to generate most of
the cell lines studied. Since the first experiments using integrating
retroviral vectors, various approaches to deliver the reprogramming
genes have been described, most notably newer integration-free and
viral-free methods (Stadtfeld & Hochedlinger, 2010; Bellin et al,
2012; Robinton & Daley, 2012). These new techniques avoid inser-
tional mutagenesis and transgene reactivation and can minimize
variability between reprogrammed cell lines. While non-integrating
methods can benefit both disease modeling and the future use in cell
transplantation therapies, many excellent studies of disease model-
ing have used the retroviral system (Bellin et al, 2012). This may, in
part, be explained by the limited protocol efficiencies of the new
methods. Among the newer techniques, episomal plasmids and
Sendai virus are the more commonly used (Okita et al, 2011;
Chumarina et al, 2019), but reprogramming using synthetic mRNAs
is also possible. As the non-integrating reprogramming technology
improves, these technologies will be preferred in future studies.
In conclusion, our previous studies on patient tissues showed
that POLG mutations lead to neuronal mtDNA depletion and, given
sufficient time, point mutations and deletions (Tzoulis et al, 2013,
2014). Our current studies confirm that there is loss of ATP and
membrane potential that we believe leads to changes in redox
potential and excess ROS production. We also find activation of
mitophagy. Our hypothesis is that neuronal death occurs by two
mechanisms: Firstly, the initiation of seizures in already stressed
neurons exceeds the capacity of this neuron to maintain cellular
energy production and thus cellular integrity and leads to acute
neuronal death. Secondly, the loss of ATP with changes in redox
potential and ROS production lead to neuronal dysfunction that
eventually leads to chronic neuronal loss (Fig 9).
◀ Figure 8. NAD+ metabolism, ROS overproduction, exhibition of a senescence phenotype through UCP2/SirT1 and mitophagy activation via BNIP3.A–C LC-MS-based metabolomics for quantitative measurements of NAD+/NADH ratio (A, n = 3, technical replicates per clone), NAD+ (B, n = 3, technical replicates per
clone), and NADH (C, n = 3, technical replicates per clone) level in NSCs.
D–F LC-MS-based metabolomics for quantitative measurement of NAD+/NADH ratio (D, n = 3, technical replicates per clone), NAD+ (E, n = 3, technical replicates per
clone), and NADH (F, n = 3, technical replicates per clone) level in iPSCs.
G Intracellular ROS production measurements of the specific ROS level calculated by total ROS/MTDR in control, WS5A, and CP2A iPSC-derived NSCs using DCFDA and
MTDR (n = 6, technical replicates per clone for control; n = 5, technical replicates per clone for WS5A; n = 3, technical replicates per clone for CP2A).
H Flow cytometric measurements of mitochondrial ROS production at the specific ROS level in Detroit 551, WS5A, and CP2A iPSC-derived NSCs calculated by total
ROS (MitoSox Red)/MTG (n = 4, technical replicates per clone for control and CP2A; n = 3, technical replicates per clone for WS5A).
I, J Representative images of senescence b-galactosidase staining (scale bars, 20 lm) (I) and quantification by calculating the percentage of positively stained cells by
division of the negative cells from I (J, n = 3, technical replicates per clone).
K, L Representative images (K) and quantification (L) for western blotting with Phospho-SirT1 (Ser47), LC3B, UCP2, PINK1, Parkin, BNIP3, and b-ACTIN. Three
independent experiments are included.
Data information: The data points in A–F and H represent iPSCs or iPSC-derived NSCs from 2 different clones from Detroit 551 control, 3 different clones from WS5A
patient iPSCs, and 2 different clones from CP2A patient iPSCs. The data points in G represent NSCs generated from 5 different control iPSCs including 4 clones from
Detroit 551 control and one clone from control AG05836, 3 clones from WS5A patient iPSCs, and 2 clones from CP2A patient iPSCs. The data points in J represent NSCs
generated from 2 different clones from Detroit 551 control, 2 different clones from WS5A patient iPSCs, and 2 different clones from CP2A patient iPSCs. The data points in
L represent NSCs generated from 2 to 3 different clones from Detroit 551 control and 3 different clones from WS5A patient iPSCs and 2–3 different clones from CP2A
patient iPSCs. Data are presented as mean  SEM for the number of samples. Mann–Whitney U-test was used for the data presented in G, L, e, and L, f. Two-sided
Student’s t-test was used for the data presented in A–F, H, J, and L, a–d. Significance is denoted for P values of less than 0.05. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001.
Source data are available online for this figure.
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We believe that our studies are the first that show that it is possi-
ble to recapitulate the biochemical and molecular findings associ-
ated with the common mutations in POLG. Further, we believe that
these studies demonstrate that iPSC-derived neural stem cells
provide a robust model system in which to study tissue-specific
mitochondrial disease manifestations. Since NSCs can be grown in
large numbers in smaller formats, we hope to use this system to
establish a high-throughput screening system in order to identify
therapies for these devastating diseases. Our studies indicate further
that the health potential of targeting NAD+ homeostasis will inform




The project was approved by the Western Norway Committee for
Ethics in Health Research (REK nr. 2012/919). Tissues were
acquired with written informed consent from all patients, and the
experiments conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report.
Derivation of iPSCs
Skin fibroblasts from one homozygous c.2243G>C, p.W748S/
W748S (WS5A) and one compound heterozygous c.1399G>A/
c.2243G>C, p.A467T/W748S (CP2A) patient were collected by
punch biopsy and cultured in DMEM/F12, GlutaMAXTM (Thermo
Fisher Scientific, cat. no. 10565018) with 10% (v/v) FBS
(Sigma-Aldrich, cat. no. 12103C), 20 mM glutamine (Sigma-
Aldrich, cat. no. G7513), 10 mM sodium pyruvate (Invitrogen,
cat. no. 11360 070), and 0.5 mM uridine (Sigma-Aldrich, cat.
no. U 3003). Detroit 551 (control 1, ATCC CCL 110TM, human
normal fetal female fibroblast), CCD-1079Sk (control 2, ATCC
CRL-2097TM, human normal new-born male fibroblast), and
AG05836 (control 3, RRID:CVCL2B58, 44-year-old female fibrob-
lasts) were used as controls. Control fibroblasts were grown in
Figure 9. Summary of the possible disease mechanisms in neuronal cells with POLG mutations.
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DMEM/F12, GlutaMAXTM (Thermo Scientific, cat. no. 35050061)
with 10% (v/v) FBS.
We reprogrammed Detroit 551 and CCD-1079Sk control fibrob-
lasts, and patient fibroblasts using retroviral vectors encoding
POU5F1, SOX2, Klf4, and c Myc as previously described (Siller
et al, 2016). AG05836 control fibroblasts were reprogrammed by
Sendai virus vectors. We also employed two human embryonic
stem cell lines (hESCs) as controls: The hESC line 360 (male) was
obtained from the Karolinska Institute, Sweden, (Strom et al,
2010) and H1 (male) from WiCell Research Institute (Thomson
et al, 1998).
Both iPSC and hESC lines were maintained under feeder-free
conditions using Geltrex (Invitrogen, cat. no. A1413302) in E8
medium (Invitrogen, cat. no. A1517001) in 6-well plates (Thermo
Scientific, cat. no. 140675). Each line was passaged with 0.5 mM
EDTA (Invitrogen, cat. no. 15575038) at 70–80% confluency. The
E8 was changed every day, and the cells passaged every 3–4 days.
All the cells were monitored for mycoplasma contamination regu-
larly using MycoAlertTM Mycoplasma Detection Kit (Lonza, cat. no.
LT07-218).
Neural induction
Neural induction was based on a previously described method
(Stacpoole et al, 2011) with minor modifications. Briefly, 70% con-
fluent iPSCs were split and seeded onto feeder-free Geltrex-coated
plates in E8 medium. After 24 h, the medium was changed to
neural induction medium prepared by addition of 10 lM SB431542
(Tocris Bioscience, cat. no. 1614), 10 lM N Acetyl L cysteine
(NAC, Sigma-Aldrich, cat. no. A7250), and 2 lM AMPK inhibitor
Compound C (EMD Millipore, cat. no. US1171261 1MG) to Chemi-
cally Defined Medium (CDM) containing 50% Iscove’s Modified
Dulbecco’s Medium (IMDM, Invitrogen, cat. no. 21980 065), 50%
F12 Nutrient Mixture (Ham) liquid with GlutaMAXTM, 5 mg/ml
bovine serum albumin (BSA) Fraction V (Europa bioproducts ITD,
cat. no. EQBAC62 1000), 1% (v/v) Lipid 100 X (Invitrogen, cat.
no. 11905 031), 450 lM 1 thioglycerol (Sigma-Aldrich, cat. no.
M6145 25ML), 7 lg/ml insulin (Roche cat. no. 11376497001), and
15 mg/ml transferrin (Roche, cat. no. 10652202001). Medium was
changed daily until cells reached the neural epithelial stage at day
5. The cells were then detached by incubation with collagenase IV
(Invitrogen, cat. no. 17104 019) at 37°C for 1 min. After incuba-
tion, the cells were washed with DPBS without calcium and
magnesium (DPBS/) before addition of StemProTM NSC medium
supplemented with 1× GlutaMAXTM, bFGF, and EGF (Thermo
Fisher, cat. no. A1050901). Spheres were then generated by scrap-
ing a grid pattern at the bottom of each well using a pipette tip,
and the cell suspensions transferred into 100 mm Corning non-
treated culture dishes (Sigma-Aldrich, cat. no. CLS430591) and
incubated at 37°C on an orbital shaker (Fisher Scientific, cat. no.
SGM 250 030K). After 2–3 days, the spheres were collected and
dissociated into single cells by incubation with TrypLETM Express
at 37°C for 10 min followed by trituration. After neutralization
with DMEM with 10% (v/v) FBS, the cell pellet was reconstituted
in StemPro NSC medium and seeded on Geltrex-coated 6-well
plates as monolayer NSCs. All the NSCs used for further analysis
was limited to passages 4–9 in order to maintain them as primary
lines.
Mitochondrial volume and MMP measurement
To measure mitochondrial volume and MMP, cells were double-
stained with 150 nM MitoTracker Green (MTG) (Invitrogen, cat. no.
M7514) and 100 nM TMRE (Abcam, cat. no. ab113852) for 45 min
at 37°C. Cells treated with 100 lM FCCP (Abcam, cat. no.
ab120081) were used as negative control. Stained cells were washed
with PBS, detached with TrypLETM Express, and neutralized with
media containing 10% FBS. The cells were immediately analyzed
on a FACS BD AccuriTM C6 flow cytometer (BD Biosciences, San
Jose, CA, USA). The data analysis was performed using AccuriTM C6
software. For each sample, more than 40,000 events were analyzed,
and doublets or dead cells excluded.
Mitochondrial DNA quantification and deletion assessment
DNA was extracted using a QIAGEN DNeasy Blood and Tissue Kit
(QIAGEN, cat. no. 69504) according to the manufacturer’s protocol.
MtDNA quantification and depletion assessment were performed
using RT-qPCR and long range polymerase chain reaction (Long-
PCR) as previously described (Tzoulis et al, 2014).
Hepatocyte differentiation
Hepatocyte differentiation from iPSCs was optimized for patient and
control lines using a previously established approach (Siller et al,
2015, 2016; Siller & Sullivan, 2017). Terminal differentiation to
hepatocyte-like cells was performed using the optimal conditions
identified above and following a previously reported small molecule
driven protocol (Siller et al, 2015; Mathapati et al, 2016).
Immunohistochemistry for identifying the hepatocytes was
performed as previously described (Siller et al, 2015, 2016; Mathap-
ati et al, 2016; Siller & Sullivan, 2017). Images were obtained using
a Zeiss LSM700 Confocal microscope (Carl Zeiss Meditec AG,
Germany).
Cardiomyocyte differentiation
Cardiomyocyte differentiation was done utilizing a well-established
protocol for generating cardiomyocytes through sequential activa-
tion and inhibition of Wnt signaling pathway (Lian et al, 2013).
Karyotype analyses
Human G banding karyotyping was performed using standard meth-
ods. For each cell line, 20 chromosomes were analyzed from live or
fixed cells in metaphase. The analysis was performed using G band-
ing and Leishman stain, and the cells were analyzed according to
the Clinical Cytogenetics Standards and Guidelines published by the
American College of Medical Genetics (Meisner & Johnson, 2008).
Glial cells and DA neuron differentiation
For astrocyte differentiation, NSCs were plated on poly-D-lysine
(PDL)-coated coverslips (Neuvitro, cat. no. GG-12-15-PDL). The
following day, the cells were washed with DPBS/ and cultured in
astrocyte differentiation medium: DMEM/F-12, GlutaMAXTM supple-
mented with 1× N2 (Invitrogen, cat. no. 17502-048), 1× B27
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(Invitrogen, cat. no. 17504044-10 ml), 200 ng/ml insulin-like
growth factor-I (IGF-I) (Sigma-Aldrich, cat. no. I3769-50UG), 10 ng/
ml heregulin 1b (Sigma-Aldrich cat. no. SRP3055-50UG), 10 ng/ml
activin A (PeproTech, cat. no. 120-14E), 8 ng/ml FGF2 (PeproTech,
cat. no. 100-18B), and 1% FBS. The medium was changed every
other day for the first week, every 2 days for the second week, and
every 3 days for the third and fourth week.
After 28 days of differentiation, the cells were cultured in matu-
ration medium AGMTM Astrocyte Growth Medium BulletKitTM
(Lonza, cat. no. CC-3186), including Astrocyte Basal Medium
supplemented with ascorbic acid, rhEGF, Gentamicin Sulfate/
Amphotericin (GA-1000), insulin, L-glutamine, and FBS for one
more month.
For glial oligodendrocyte differentiation, NSCs were plated at dif-
ferent cell densities onto surfaces coated with PDL or 0.01% poly-L-
ornithine (Sigma-Aldrich, cat. no. P4957) and 5 lg/ml laminin
(Sigma-Aldrich, cat. no. L2020). After 2 days, differentiation was
performed according to commercial protocol (Invitrogen). Briefly,
oligodendrocyte differentiation medium was supplemented with 1×
Neurobasal medium (Invitrogen, cat. no.: 21103049) with 2% B27
Serum Free Supplement, 2 mM GlutaMAXTM, and 30 ng/ml
triiodothyronine (T3) (Sigma-Aldrich, cat. no. D6397). Differentiat-
ing oligodendrocyte cells were kept in these conditions, and the
medium was changed every other day.
For DA neuron differentiation, neurospheres generated from
neural induction were maintained in CDM supplemented with
100 ng/ml FGF8b (R&D systems, cat. no. 423-F8) over a period of
7 days to initiate DA progenitor induction. The following 7 days,
the medium was changed to CDM supplemented with 1 lM PM
(EMD Millipore, cat. no. 540220-5MG) and 100 ng/ml FGF-8. Termi-
nation of the suspension cultures was performed by dissociating the
spheres into single cells by incubation with TrypLETM Express
followed by trituration and subsequent plating into monolayers. The
DA neurons were matured in DA medium: CDM supplemented with
10 ng/ml BDNF (PeproTech, cat. no. 450-02) and 10 ng/ml GDNF
(PeproTech, cat. no. 450-10) on poly-L-ornithine (Sigma-Aldrich,
cat. no. P4957) and laminin (Sigma-Aldrich, cat. no. L2020)-coated
plates.
Immunocytochemistry and immunofluorescence (ICC/IF)
Cells were fixed with 4% (v/v) paraformaldehyde (PFA, VWR, cat.
no. 100503 917) and blocked using blocking buffer containing 1×
PBS, 10% (v/v) normal goat serum (Sigma-Aldrich, cat. no. G9023)
with 0.3% (v/v) TritonTM X-100 (Sigma-Aldrich, cat. no. X100-
100ML). The cells were then incubated with primary antibody solu-
tion overnight at 4°C and further stained with secondary antibody
solution (1:800 in blocking buffer) for 1 h at RT. IPSCs were stained
for pluripotent markers using the primary antibodies rabbit Anti-
SOX2 (Abcam, cat. no. ab97959, 1:100), rabbit Anti-POU5F1
(Abcam, cat. no. ab19857, 1:100), and mouse Anti-SSEA4 [MC813]
(Abcam, cat. no. ab16287, 1:200). NSCs were stained with rabbit
Anti-PAX6 (Abcam, cat. no. ab5790, 1:100), mouse Anti-NESTIN
(10c2) (Santa Cruz Biotechnology, cat. no. sc23927, 1:50), rabbit
Anti-SOX2, and mitochondrial complex I subunit rabbit Anti-
NDUFB10 (Abcam, cat. no. ab196019, 1:1,000). Astrocytes and
oligodendrocytes were stained with chicken Anti-GFAP (Abcam cat.
no. ab4674, 1:400), rabbit Anti-S100b (Abcam cat. no. ab196442,
1:100), rabbit Anti-EAAT1 (Abcam cat. no. ab416, 1:200), mouse
Anti-Glutamine Synthetase (Abcam cat. no. ab64613, 1:200), rabbit
Anti-GALC (Abcam cat. no. ab2894, 1:200), rabbit Anti-OLIGO2
(Abcam cat. no. ab42453, 1:1,000), and rabbit Anti-MBP (Abcam
cat. no. ab62631, 1:500) respectively. The antibodies used for DA
neuron staining were rabbit Anti-tyrosine hydroxylase (Abcam, cat.
no. ab75875, 1:100), mouse Anti-Beta III Tubulin (Abcam, cat. no.
ab78078, 1:1,000), and chicken Anti-MAP2 (Abcam, cat. no.
ab5392, 1:100). The secondary antibodies used were Alexa Flour
goat Anti-rabbit 488 (Thermo Fisher Scientific, cat. no. A11008,
1:800), Alexa Flour goat Anti-rabbit 594 (Thermo Fisher Scientific,
cat. no. A11012, 1:800), Alexa Flour goat Anti-mouse 594 (Thermo
Fisher Scientific, cat. no. A11005, 1:800), and Alexa Flour goat
Anti-chicken 594 (Thermo Fisher Scientific, cat. no. A11042, 1:800).
After incubation with secondary antibodies, the coverslips were
mounted onto cover slides using Prolong Diamond Antifade Moun-
tant with DAPI (Invitrogen, cat. no. P36962).
For staining of neurospheres, spheres were spread directly onto
cover slides and left at RT until completely dry and then fixed with
4% (v/v) PFA. After two washes with PBS, the spheres were
covered in PBS with 20% sucrose, sealed with parafilm, and incu-
bated overnight at 4°C. The spheres were blocked with blocking
buffer for 2 h at RT, and the primary antibodies were added to the
samples overnight at 4°C. After washing the samples for 3 h in PBS
with a few changes of buffer, incubation with secondary antibodies
(as described above) was conducted overnight at 4°C in a humid
and dark chamber. Coverslips were mounted using Fluoromount-G
(Southern Biotech, cat. no. 0100 01) before imaging was performed
using the Leica TCS SP5 or SP8 confocal microscope (Leica
Microsystems, Germany).
ATP generation assay
The Luminescent ATP Detection Assay Kit (Abcam, cat. no.
ab113849) was used to investigate intracellular ATP production.
Cells were cultured in a Corning 96-well flat, clear bottom, white
wall plate (Life Sciences, cat. no. 3601), and ATP measurements
were performed according to the manufacturer’s protocol when cells
had reached 90% confluence. The kit irreversibly inactivates ATP
degrading enzymes (ATPases) during the lysis step and measures
the luminescent signal corresponding to the endogenous levels of
ATP. Three to six replicates were measured for each sample. Lumi-
nescence intensity was monitored using the Victor XLight Multi-
mode Plate Reader (PerkinElmer). To normalize the value with cell
number, cells grown on the same 96-well plates were incubated
with Janus Green cell normalization stain after manufacturer’s
instructions (Abcam, cat. no. ab111622). OD 595 nm was measured
using the Labsystems Multiskan Bichromatic plate reader (Titertek
Instruments, USA).
ROS production
Intracellular ROS production was measured by flow cytometry using
dual staining of 30 lM DCFDA (Abcam, cat. no. b11385) and
150 nM MTDR (Invitrogen, cat. no. M22426), which enabled us to
assess ROS level related to mitochondrial volume. Mitochondrial
ROS production was quantified using co-staining of 10 lM Mito-
SOXTM red mitochondrial superoxide indicator (Invitrogen, cat. no.
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M36008) and 150 nM MTG to evaluate ROS level in relation to mito-
chondrial volume. Stained cells were detached with TrypLETM
Express and neutralized with media containing 10% FBS. The cells
were immediately analyzed on a FACS BD AccuriTM C6 flow cytome-
ter. For each sample, more than 40,000 events were recorded, and
doublets or dead cells excluded before data analysis was performed
using the AccuriTM C6 software.
NAD+ metabolism measurement using LC-MS analysis
Cells were washed with PBS and extracted by addition of ice-cold
80% methanol followed by incubation at 4°C for 20 min. Thereafter,
the samples were stored at 80°C overnight. The following day,
samples were thawed on a rotating wheel at 4°C and subsequently
centrifuged at 16,000 g and 4°C for 20 min. The supernatant was
added to 1 volume of acetonitrile, and the samples were stored at
80°C until analysis. The pellet was dried and subsequently recon-
stituted in lysis buffer (20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2%
SDS, 1 mM EDTA) to allow for protein determination (BCA assay).
Separation of the metabolites was achieved with a ZIC-pHILC
column (150 × 4.6 mm, 5 lm; Merck) in combination with the
Dionex UltiMate 3000 (Thermo Scientific) liquid chromatography
system. The column was kept at 30°C. The mobile phase
consisted of 10 mM ammonium acetate pH 6.8 (Buffer A) and
acetonitrile (Buffer B). The flow rate was kept at 400 ll/min, and
the gradient was set as follows: 0 min 20% Buffer B, 15 min to
20 min 60% Buffer B, and 35 min 20% Buffer B. Ionization was
subsequently achieved by heated electrospray ionization facilitated
by the HESI-II probe (Thermo Scientific) using the positive ion
polarity mode and a spray voltage of 3.5 kV. The sheath gas flow
rate was 48 units with an auxiliary gas flow rate of 11 units and
a sweep gas flow rate of 2 units. The capillary temperature was
256°C, and the auxiliary gas heater temperature was 413°C. The
stacked-ring ion guide (S-lens) radio frequency (RF) level was at
90 units. Mass spectra were recorded with the QExactive mass
spectrometer (Thermo Scientific), and data analysis was
performed with the Thermo Xcalibur Qual Browser. Standard
curves generated for NAD+ and NADH were used as reference for
metabolite quantification.
NAD+ metabolism measurement using colorimetric analysis
The ratio of NAD+/NADH was quantified with a commercial
NAD+/NADH Quantitation Colorimetric Kit (BioVision, cat. no.
K337) according to the manufacturer’s instructions and as previ-
ously described (Gomes et al, 2012).
Protein level assessment of TFAM and mitochondrial respiratory
chain complexes
Cells were detached with TrypLETM Express, pelleted, and fixed in
1.6% (v/v) PFA at RT for 10 min, before permeabilization with ice-
cold 90% methanol at 20°C for 20 min. The cells were blocked
using buffer containing 0.3 M glycine, 5% goat serum, and 1% BSA
in PBS. For TFAM expression, cells were stained with Anti-TFAM
antibody conjugated with Alexa Fluor 488 (Abcam, cat. no.
ab198308, 1:400) and Anti-TOMM20 antibody conjugated with
Alexa Fluor 488 (Santa Cruz Biotechnology, cat. no. sc 17764
AF488, 1:400), separately. Staining of mitochondrial respiratory
chain complexes was conducted using primary antibodies Anti-
NDUFB10 (Abcam, cat. no. ab196019, 1:1,000), Anti-SDHA
[2E3GC12FB2AE2] (Abcam, cat. no. ab14715, 1:1,000), and Anti-
COX IV [20E8C12] (Abcam, cat. no. ab14744, 1:1,000), followed by
secondary antibody incubation (1:400). The cells were immediately
analyzed on BD AccuriTM C6 flow cytometer, and AccuriTM C6 soft-
ware was used for data analysis. Both dot plots of SSC-H/SSC-A and
FSC-H/FSC-A were used to exclude duplicates. For each sample,
more than 40,000 events were recorded.
Western blotting
Extraction of protein was performed using 1× RIPA lysis buffer
(Sigma-Aldrich, cat. no. R0278) supplemented with HaltTM Protease
and Phosphatase Inhibitor Cocktail (Invitrogen, cat. no. 78444).
Protein concentration was determined using BCA protein assay
(Thermo Fisher Scientific, cat. no. 23227). The cell protein was
loaded into NuPAGETM 4–12% Bis-Tris Protein Gels (Invitrogen, cat.
no. NP0321PK2) and resolved in PVDF membrane (Bio-Rad, cat. no.
1704157) using the Trans-Blot TurboTM Transfer System (Bio-Rad,
Denmark). Membranes were blocked with 5% non-fat dry milk or
5% BSA in TBST for 1 h at RT. Membranes were then incubated
overnight at 4°C with rabbit monoclonal IgG Anti-UCP2 (1:1,000,
Cell Signalling, cat. no. 89326), rabbit polyclonal IgG Anti-Phospho-
SirT1 (Ser47) (1:2,000, Cell Signalling, cat. no. 2314), rabbit poly-
clonal IgG Anti-PINK1 (1:500, Proteintech, cat. no. 23274-1-AP),
rabbit polyclonal IgG Anti-Parkin (1:500, Proteintech, cat. no.
14060-1-AP), rabbit polyclonal IgG Anti-LC3B (1:3,000, Abcam, cat.
no. ab51520), rabbit polyclonal Anti-BNIP3 (1:1,000, Abcam, cat.
no. ab10962) or rabbit polyclonal IgG Anti-UCP2 (1:500, Protein-
tech, cat. no. 11081-1-AP), and mouse monoclonal IgG Anti-b-
ACTIN antibody conjugated to HRP (1:5,000, Abcam, cat. no.
ab49900) as a control. After washing in TBST, membranes were
incubated with donkey Anti-mouse monoclonal antibody or swine
Anti-rabbit monoclonal antibody conjugated to HRP secondary anti-
body (Jackson ImmunoResearch, 1:1,000), for 1 h at RT. Super
Signal West Pico Chemiluminescent Substrate (Thermo Fisher Scien-
tific, cat. no. 34577) was used as enzyme substrate according to
manufacturer’s recommendations. The membranes were visualized
in SynGene scanner (VWR, USA).
b-galactosidase staining assay
b-galactosidase activity was detected by using a Senescence b-galac-
tosidase Staining Kit (Cell Signaling, cat. no. 9860) according to the
manufacturer’s instructions. The cells were seeded in complete
media into 6-well plates with coverslips. After 24 h-incubation, the
cells were fixed with 1× fixative solution and incubated with the b-
galactosidase staining solution overnight at 37°C in a dry incubator
without CO2. Afterward, cells were observed, and images were
captured under Nikon TE2000 fluorescence microscope.
Tissue studies
Formalin-fixed, paraffin-embedded (FFPE), and fresh frozen brain
tissues were available from patients with POLG disease (n = 5) and
neurologically healthy controls (n = 5) who were demographically
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matched. Informed consent was obtained from all subjects and that
the experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. The POLG mutations for these patients are
A467T/G303R (AL-1B); A467T/A467T (AT-1A); A467T/A467T (AT-
2A); W748S/W748S (WS-10A); and W748S/W748S (WS-3A).
Patient IDs used in our previous publications were shown in paren-
thesis to allow comparison with results of our earlier work. There
were no statistically significant differences in post-mortem interval
or length of fixation between patient and control tissue. Samples
were dissected at autopsy and either snap-frozen immediately in
isopentane, which had been cooled in liquid nitrogen, and stored at
80°C, or fixed in formaldehyde and later embedded in paraffin
blocks according to standard procedures.
Mitochondrial complex I immunohistochemistry was performed
on 4-lm sections of formalin-fixed, paraffin-embedded tissue from
the primary occipital cortex of three patients and two neurologically
healthy controls as previously described (Tzoulis et al, 2014).
Neurons for mtDNA analysis were microdissected from frozen
sections of primary occipital (Brodmann area 17) from five patients
and five age-matched controls. Microdissection and cell lysis were
carried out as previously described (Tzoulis et al, 2013). Only cells
that could be positively identified as neurons, with a visible nucleus
and normal morphological characteristics, were used. For each area,
there was no significant size difference between neurons of patients
and corresponding controls. A total of 400 neurons were picked from
5 patients (n = 200) and five age-matched controls (n = 200).
Neurons were microdissected, avoiding carryover of glia or other
cells, and pooled in 3–5 groups of 10 cells per individual. MtDNA copy
number quantification was performed in microdissected neurons by
qRT-PCR, using TaqMan fluorogenic probes and a 7500 fast sequence
detection system (ABI) as previously described (Tzoulis et al, 2013).
Gene expression
Total RNA was isolated using MagMAXTM 96 Total RNA isolation Kit
(Thermo Fisher Scientific, cat. no. AM1830). High-throughput
MagMAXTM Express 96 was employed to extract RNA from the cell
lysate.
EXPRESS One Step SuperscriptTM RT-qPCR Kit (Thermo Fisher
Scientific, cat. no. 11781 200) and TaqManTM Probes were recruited
to perform cDNA synthesis and RT-qPCR in one step. Applied
Biosystems 7500 Fast Real-Time PCR machine (Thermo Fisher
Scientific) was used to perform qRT-PCR. TaqManTM probes (Life
Technologies) for POU5F1 (Hs00999634), NANOG (Hs04260366),
PAX6 (Hs01088114), NESTIN (Hs04187831), and LIN28A
(Hs00702808) were used. The average CT values of three technical
replicates were normalized to the geometric mean of endogenous
control gene, Actin Beta (ACTB: Hs01060665). The expression of the
iPSC markers was assessed with fold change by using the compara-
tive DDCt method by normalizing the gene level from ESC1. The
expression of the NSC markers was assessed with fold change by
using the comparative DDCt method by normalizing NSCs to iPSCs.
DNA sequencing for POLG mutations
Forward and backward oligonucleotide primers were used to
amplify the 7 exons and 13 exons of the POLG gene, as reported
elsewhere (Hakonen et al, 2005). Automated nucleotide sequencing
was performed using the Applied BiosystemsTM BigDye Terminator
v3.1 Cycle Sequencing Kit (Invitrogen, cat. no. 4337454) and
analyzed on an ABI3730 Genetic Analyzer with sequencing analyzer
software ChromasPro (Technelysium Pty Ltd, Australia). The
primers designed for seven exons in POLG 1 gene were: forward, 50
TGTAAAACGACGGCCAGTGAAAGAACTGAG GCTCCGAG 30 and
reverse, 50 CAGGAAACAGCTATGACCCCTACAGAGCCA GTCCACT
30. The primers designed for 13 exons in POLG1 gene were: forward,
50 TGTAAAACGACGGCCAGTATTTCCCAGCTG ATGACGAC 30 and
reverse, 50 CAGGAAACAGCTATGACCTGCCACCCGACT TTCATTAG
30. DNA Chromatogram was aligned with the best matching human
sequences in NCBI Trace.
Data analysis
In order to minimize the phenotypic diversity caused by intraclonal
heterogeneity which is a common issue for iPSC-related studies,
multiple clones in each line were included in the all the analysis and
more than three biological repeats were conducted for each clone to
ensure adequate power to detect a prespecified effect size. Data
were presented as mean  standard error of the mean (SEM) for
the number of samples (n ≥ 3 per clone). Distributions were tested
for normality using the Shapiro–Wilk test. Outliers were detected
using interquartile range (IQR) and Tukey0s Hinges test. Mann–
The paper explained
Problem
Mitochondrial diseases are the most common with inborn errors of
metabolism and mutations in POLG, the gene encoding the catalytic
subunit of the mitochondrial DNA polymerase gamma, the most
common subgroup. These diseases are often associated with catas-
trophic involvement of the brain, and currently, there are no cures
and no robust models to study disease mechanisms in neuronal
tissue. We used neural stem cells (NSCs) produced from patient
induced pluripotent stem cells (iPSCs) to study disease mechanisms.
Results
We generated iPSCs containing two founder mutations (W748S
homozygous; W748S/A467T compound heterozygous) and differenti-
ated these into NSCs. These neural precursors manifested features
that faithfully replicated the molecular and biochemical changes
found in patient post-mortem brain tissue, namely mtDNA depletion
and loss of complex I. We also confirmed the same phenotypes in
dopaminergic neurons generated from these iPSCs. POLG-driven mito-
chondrial dysfunction also led to neuronal ROS overproduction,
increased cellular senescence, and disturbed NAD+ metabolism, a
feature that reflected the loss of complex I.
Impact
This is the first model of POLG disease that replicates exactly what is
seen in patient tissues. Using this system, it was possible to examine
the consequences of POLG-induced loss of mtDNA and complex I and
show how POLG mutations affects NAD+ metabolism and cellular fate.
We believe that iPSC-derived NSCs provide a robust model system in
which to study tissue specific mitochondrial disease manifestations,
and we hope to use this system to establish a high-throughput
screening system in order to identify therapies for these devastating
diseases.
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Whitney U-test was used to assess statistical significance for vari-
ables with non-normal distribution, while two-sided Student’s t-test
was applied for normal distributed variables. Data were analyzed
with SPSS software (SPSS v.25, IBM), and figures were produced by
GraphPad Prism software (Prism 7.0, GraphPad Software, Inc.).
Significance was denoted for P values of less than 0.05.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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